Prevalence of HIV , HBV , and HCV in United States blood donations, 2015–2023: The transfusion‐transmissible infections monitoring system ( TTIMS )

作者：Emilya Huseynova, James M. Haynes, Edward P. Notari, Brian Custer, Rita Reik, Jed B. Gorlin, Artur Belov, Hong Yang, Roger Y. Dodd, Susan L. Stramer · 发表于：Transfusion · 年份：2025 · DOI：10.1111/trf.18424 · 被引用次数：4 · 研究领域：Blood donation and transfusion practices、Hepatitis B Virus Studies、Blood transfusion and management

BACKGROUND: The Transfusion-Transmissible Infections Monitoring System assesses trends in ~60% of the US blood supply. Donors with high-risk behaviors, including injection drug users, men having sex with other men, or those exchanging sex for money/drugs, were deferred for 12 months (12 M) from 2016 to 2020 and 3 months (3M) from 2020 to 2023. Here we evaluate HIV, HBV, and HCV donation prevalence annually from 2015 to 2023 and in two comparison periods of pre-3M (2015-2020) and 3M (2020-2023) to identify differences between the two periods. METHODS: Annual prevalence was assessed for 8 TTIMS years (2015-2023) and compared between the pre-3M and 3M periods. HIV, HBV, and HCV prevalence/100,000 donations (phtd) was calculated based on serology and nucleic acid testing results. Negative binomial regression assessed prevalence using 1-year intervals. Fisher's exact test evaluated prevalence changes between the two periods (α = 0.05). RESULTS: Annual HIV and HBV prevalence remained stable, changing slightly from year 1 to 8 (2.5-2.1 phtd for HIV and 6.3-6.6 phtd for HBV). HCV prevalence declined (19.7-9.6 phtd; p <.01). HIV (2.5-2.0 phtd) and HCV (18.4-9.8 phtd) prevalence decreased from pre-3M to 3M (p <.01), while HBV prevalence remained stable (6.5-6.2 phtd; p = .06). CONCLUSIONS: Despite reducing donor deferral periods for many infectious risk behaviors, HIV and HBV prevalence were stable, while HCV prevalence declined over 8 years. Either slight or significant declines occur...